Brief: Biomarin Pharmaceutical Inc - Estimates $3.2 Billion In Total Revenues For FY - SEC Filing
12/01/2026 21:51
Jan 12 (Reuters) - SEC Filing: BIOMARIN PHARMACEUTICAL INC - ESTIMATES $3.2 BILLION IN TOTAL REVENUES FOR FY - SEC FILING BIOMARIN PHARMACEUTICAL INC - EXPECTS $230-$260 MILLION ASSET WRITE-DOWN FOR ROCTAVIAN IN Q4- SEC FILING BIOMARIN PHARMACEUTICAL INC - OUTLOOK 2025 FY NON-GAAP DILUTED EPS REMAINS UNCHANGED BIOMARIN PHARMACEUTICAL INC: ROCTAVIAN REVENUE TO BE EXCLUDED FROM 2026 GUIDANCE- PRESENTATION Source text: [ID:n0001193125-26-010508] Further company coverage: BMRN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioMarin Pharmaceutical
See all newsUS RESEARCH ROUNDUP-Analog Devices, IBM, Qualcomm
Brief: Biomarin Pharmaceutical Expects Q3 2026 Pre-Tax Charges Of $283 Million For Bought Ipr&D Expense
Brief: Biomarin Appoints Cara Bauer As Chief People Officer
Brief: Biomarin Pharmaceutical Enters Settlement And License Agreement With Ascendis Pharma On Sept 24, 2026
U.S. STOCKS ON THE MOVE-GitLab, California utilities, Herbalife